This is a working overview of Thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
== Prevention == Up to 90% of cardiovascular disease may be preventable if established risk factors are avoided. Medical management of atherosclerosis first involves modification to risk factors–for example, via smoking cessation and diet restrictions. Prevention is generally achieved by eating a healthy diet, exercising, maintaining a normal weight, and not smoking.
== Functions == The interstitial fluid is a reservoir and transportation system for nutrients and solutes distributing among organs, cells, and capillaries, for signaling molecules communicating between cells, and for antigens and cytokines participating in immune regulation. The structure of the gel reticulum plays a role in the distribution of solutes across the interstitium, as the microstructure of the extracellular matrix in some parts excludes larger molecules (exclusion volume). The density of the collagen matrix fluctuates with the fluid volume of the interstitium. Increasing fluid volume is associated with a decrease in matrix fiber density, and a lower exclusion volume. The total fluid volume of the interstitium during health represents about 20% of body weight, but the interstitial space is dynamic and may change in volume and composition during immune responses and in conditions such as cancer, specifically within the interstitium of tumors. The amount of interstitial fluid varies from about 50% of the tissue weight in skin to about 10% in skeletal muscle. Interstitial fluid pressure is variable, ranging from −1 to −4 mmHg in tissues like the skin, intestine and lungs to 21 to 24 mmHg in the liver, kidney and myocardium. Generally, increasing interstitial volume is associated with increased interstitial pressure and microvascular filtration.
Curium ion in solution almost always has a +3 oxidation state, the most stable oxidation state for curium. A +4 oxidation state is seen mainly in a few solid phases, such as CmO2 and CmF4. Aqueous curium(IV) is only known in the presence of strong oxidizers such as potassium persulfate, and is easily reduced to curium(III) by radiolysis and even by water itself. The chemical behavior of curium is different from the actinides thorium and uranium, and is similar to americium and many lanthanides. In aqueous solution, the Cm3+ ion is colorless to pale green; Cm4+ ion is pale yellow. The optical absorption of Cm3+ ion contains three sharp peaks at 375.4, 381.2 and 396.5 nm and their strength can be directly converted into the concentration of the ions. The +6 oxidation state has only been reported once in solution in 1978, as the curyl ion (CmO2+2): this was prepared from beta decay of americium-242 in the americium(V) ion 242AmO+2. Failure to get Cm(VI) from oxidation of Cm(III) and Cm(IV) may be due to the high Cm4+/Cm3+ ionization potential and the instability of Cm(V). Curium ions are hard Lewis acids and thus form most stable complexes with hard bases. The bonding is mostly ionic, with a small covalent component. Curium in its complexes commonly exhibits a 9-fold coordination environment, with a tricapped trigonal prismatic molecular geometry.
Although the error rate for both whites and blacks was calibrated equal at exactly 61%, the errors for each race were different—the system consistently overestimated the chance that a black person would re-offend and would underestimate the chance that a white person would not re-offend. In 2017, several researchers showed that it was mathematically impossible for COMPAS to accommodate all possible measures of fairness when the base rates of re-offence were different for whites and blacks in the data. A program can make biased decisions even if the data does not explicitly mention a problematic feature (such as "race" or "gender"). The feature will correlate with other features (like "address", "shopping history" or "first name"), and the program will make the same decisions based on these features as it would on "race" or "gender". Moritz Hardt said "the most robust fact in this research area is that fairness through blindness doesn't work." Criticism of COMPAS highlighted that machine learning models are designed to make "predictions" that are only valid if we assume that the future will resemble the past. If they are trained on data that includes the results of racist decisions in the past, machine learning models must predict that racist decisions will be made in the future. If an application then uses these predictions as recommendations, some of these "recommendations" will likely be racist. Thus, machine learning is not well suited to help make decisions in areas where there is hope that the future will be better than the past.
==== German policy ==== There are sources that highlighted the more favorable treatment of the Czechs during the German occupation in comparison to the treatment of the Poles and the Ukrainians. This is attributed to the view within the Nazi hierarchy that a large swath of the populace was "capable of Aryanization," hence, the Czechs were not subjected to a similar degree of random and organized acts of brutality that their Polish counterparts experienced. Such capacity for Aryanization was supported by the position that part of the Czech population had German ancestry. On the other hand, the Czechs/Slavs were not considered by the Germans as a racial equal due to its classification as a mixture of races with Jewish and Asiatic influences. This was illustrated in a series of discussion, which denigrated it as less valuable and, specifically, the Czechs as "dangerous and must be handled differently from Aryan peoples."
Sources: en.wikipedia.org
Calcium sulfate (or calcium sulphate) is an inorganic salt with the chemical formula CaSO4. It occurs in several hydrated forms; the anhydrous state (known as anhydrite) is a white crystalline solid often found in evaporite deposits. Its dihydrate form is the mineral gypsum, which may be dehydrated to produce bassanite, the hemihydrate state. Gypsum occurs in nature as crystals (selenite) or fibrous masses (satin spar), typically colorless to white, though impurities can impart other hues. All forms of calcium sulfate are sparingly soluble in water and cause permanent hardness when dissolved therein.
=== Journal articles === —— (1927). "The Theoretical Prediction of the Physical Properties of Many-Electron Atoms and Ions. Mole Refraction, Diamagnetic Susceptibility, and Extension in Space". Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences. 114 (767): 181–211. Bibcode:1927RSPSA.114..181P. doi:10.1098/rspa.1927.0035. —— (1929). "The Principles Determining the Structure of Complex Ionic Crystals". Journal of the American Chemical Society. 51 (4): 1010–1026. Bibcode:1929JAChS..51.1010P. doi:10.1021/ja01379a006. —— (1931). "The Nature of the Chemical Bond. I. Application of Results Obtained from the Quantum Mechanics and from a Theory of Paramagnetic Susceptibility to the Structure of Molecules". Journal of the American Chemical Society. 53 (4): 1367–1400. Bibcode:1931JAChS..53.1367P. doi:10.1021/ja01355a027. —— (1931). "The Nature of the Chemical Bond. II. The One-Electron Bond and the Three-Electron Bond". Journal of the American Chemical Society. 53 (9): 3225–3237. Bibcode:1931JAChS..53.3225P. doi:10.1021/ja01360a004. —— (1932). "The Nature of the Chemical Bond. III. The Transition from One Extreme Bond Type to Another". Journal of the American Chemical Society. 54 (3): 988–1003. Bibcode:1932JAChS..54..988P. doi:10.1021/ja01342a022. —— (1932). "The Nature of the Chemical Bond. IV. The Energy of Single Bonds and the Relative Electronegativity of Atoms". Journal of the American Chemical Society. 54 (9): 3570–3582. Bibcode:1932JAChS..54.3570P. doi:10.1021/ja01348a011. ——; Wheland, G. W. (1933). "The Nature of the Chemical Bond. V.
== Structure == RTKs have a tripartite structure with extracellular, transmembrane, and cytoplasmic regions. This gene encodes a member of a novel subclass of RTKs and contains a distinct extracellular region encompassing a factor VIII–like domain.
== Neoantigenic determinant == A neoantigenic determinant is an epitope on a neoantigen, which is a newly formed antigen that has not been previously recognized by the immune system. Neoantigens are often associated with tumor antigens and are found in oncogenic cells. Neoantigens and, by extension, neoantigenic determinants can be formed when a protein undergoes further modification within a biochemical pathway such as glycosylation, phosphorylation or proteolysis. This, by altering the structure of the protein, can produce new epitopes that are called neoantigenic determinants as they give rise to new antigenic determinants. Recognition requires separate, specific antibodies.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.